Sign In
Buy EXEL
$53.03
-2.94 (-5.25%)
At Close: Jul 31, 2026
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
06:56pm, Wednesday, 29'th Jul 2026
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
06:56pm, Wednesday, 29'th Jul 2026
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached thei
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
05:00pm, Friday, 24'th Jul 2026
Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically do
EXEL vs. ILMN: Which Stock Is the Better Value Option?
12:41pm, Friday, 24'th Jul 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value inves
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
04:30pm, Wednesday, 22'nd Jul 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At
Bank of New York Mellon Corp Sells 57,995 Shares of Exelixis, Inc. $EXEL
03:47am, Wednesday, 22'nd Jul 2026
Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exch
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
11:01am, Monday, 20'th Jul 2026
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allspring Global Investments Holdings LLC Acquires 323,895 Shares of Exelixis, Inc. $EXEL
03:09am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 16'th Jul 2026
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Under-the-Radar Stocks to Buy and Hold
02:30pm, Friday, 10'th Jul 2026
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
03:26pm, Thursday, 09'th Jul 2026
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Stocks Look Shaky, But This Sector is Booming (Biotech)
02:06pm, Thursday, 09'th Jul 2026
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:46am, Thursday, 09'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 08'th Jul 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 08'th Jul 2026
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
